Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...
Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...
Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...
Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...
Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...
Bausch + Lomb (BLCO) announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses in the European Union after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback